4//SEC Filing
CORAUTUS GENETICS INC 4
Accession 0001181431-07-038632
CIK 0001003929operating
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 5:02 PM ET
Size
8.7 KB
Accession
0001181431-07-038632
Insider Transaction Report
Form 4
Cohen Lawrence Kenneth
DirectorCEO and President
Transactions
- Award
Stock Option (right to buy)
2007-06-05+111,516→ 111,516 totalExercise: $0.03Exp: 2015-06-29→ Common Stock (111,516 underlying) - Award
Common Stock
2007-06-05+119,660→ 119,660 total
Footnotes (5)
- [F1]Includes 54,875 shares acquired upon early exercise of vested options, which shares are subject to repurchase by VIA Pharmaceuticals, Inc. upon termination of employment and reflects a 1-for-15 reverse stock split, which became effective on June 5, 2007.
- [F2]Received in exchange for 74,285 shares of Series A Preferred Stock of VIA Pharmaceuticals, Inc. ("VIA") and 247,625 shares of VIA common stock in connection with the merger of VIA with Corautus Genetics Inc. (the "Merger") based on an exchange ratio of 0.371721.
- [F3]The exercise price reflects the exercise price of each option to purchase VIA common stock prior to the closing of the Merger divided by the exchange ratio of 0.371721.
- [F4]Received in the Merger in exchange for stock options to acquire 300,000 shares of VIA common stock at an exercise price of $0.01 per share based on an exchange ratio of 0.371721.
- [F5]25% of the shares subject to the option vested on June 29, 2005. 1/48th of the shares subject to the option vest on the 29th day of each month thereafter, subject to Dr. Cohen continuing to be a service provider through each such date.
Documents
Issuer
CORAUTUS GENETICS INC
CIK 0001003929
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001003929
Filing Metadata
- Form type
- 4
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 5:02 PM ET
- Size
- 8.7 KB